Good News in Pancreatic Cancer; Breast Screening Debate; AI May Erode Docs' Skills
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — Revolution Medicines announced that its investigational RAS inhibitor, daraxonrasib, doubled the median overall survival for previously treated advanced pancreatic cancer (13.2 versus 6.7 months) in a randomized phase III trial comparing…
